Apogee Therapeutics, Inc. Comprehensive Income
Apogee Therapeutics, Inc. (APGE) reported Comprehensive Income of -$87.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-10
- Apogee Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$87.61M.
- Apogee Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$75.94M.
- Apogee Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$69.33M.
- Apogee Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$64.68M.
- Apogee Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$255.68M.
- Apogee Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$181.56M.
- Apogee Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$83.66M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 8 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 11 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$87.61M 10-Q · filed 2026-08-10 | -$163.55M 10-Q · filed 2026-08-10 | -$232.88M derived: sum of 3 quarters · filed 2026-08-10 | -$297.56M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | -$75.94M 10-Q · filed 2026-05-11 | -$145.28M derived: sum of 2 quarters · filed 2026-05-11 | -$209.95M derived: sum of 3 quarters · filed 2026-05-11 | -$276.44M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$69.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$134.01M derived: sum of 2 quarters · filed 2026-03-02 | -$200.50M derived: sum of 3 quarters · filed 2026-08-10 | -$255.68M 10-K · filed 2026-03-02 | ||
| 2025-09-30 | -$64.68M 10-Q · filed 2025-11-10 | -$131.16M derived: sum of 2 quarters · filed 2026-08-10 | -$186.34M 10-Q · filed 2025-11-10 | -$255.92M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | -$66.48M 10-Q · filed 2026-08-10 | -$121.67M 10-Q · filed 2026-08-10 | -$191.24M derived: sum of 3 quarters · filed 2026-08-10 | -$236.70M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | -$55.18M 10-Q · filed 2026-05-11 | -$124.75M derived: sum of 2 quarters · filed 2026-05-11 | -$170.21M derived: sum of 3 quarters · filed 2026-05-11 | -$204.14M derived: sum of 4 quarters · filed 2026-05-11 | ||
| 2024-12-31 | -$69.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$115.03M derived: sum of 2 quarters · filed 2026-03-02 | -$148.96M derived: sum of 3 quarters · filed 2026-03-02 | -$181.56M 10-K · filed 2026-03-02 | ||
| 2024-09-30 | -$45.46M 10-Q · filed 2025-11-10 | -$79.39M derived: sum of 2 quarters · filed 2025-11-10 | -$111.99M 10-Q · filed 2025-11-10 | -$143.53M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-06-30 | -$33.93M 10-Q · filed 2025-08-11 | -$66.53M 10-Q · filed 2025-08-11 | -$98.07M derived: sum of 3 quarters · filed 2026-03-02 | -$118.77M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2024-03-31 | -$32.60M 10-Q · filed 2025-05-12 | -$64.14M derived: sum of 2 quarters · filed 2026-03-02 | -$84.85M derived: sum of 3 quarters · filed 2026-03-02 | -$103.73M derived: sum of 4 quarters · filed 2026-03-02 | ||
| 2023-12-31 | -$31.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$52.25M derived: sum of 2 quarters · filed 2026-03-02 | -$71.13M derived: sum of 3 quarters · filed 2026-03-02 | -$83.66M 10-K · filed 2026-03-02 | ||
| 2023-09-30 | -$20.70M 10-Q · filed 2024-11-12 | -$39.59M derived: sum of 2 quarters · filed 2024-11-12 | -$52.12M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$18.89M 10-Q · filed 2024-08-12 | -$31.41M 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | -$12.53M 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | -$39.78M 10-K · filed 2024-03-05 | |||||
| 2022-09-30 | -$19.66M 10-Q · filed 2023-11-13 | -$25.78M 10-Q · filed 2023-11-13 |